|
|
Article: Alexion Pharmaceuticals' Antibody Therapy Shown Effective in Model for Severe Allergic Asthma.
- Article from:
- PR Newswire
- Article date:
- May 15, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Findings Show Treatment with Anti-C5 Complement Antibody Reduced Airway Inflammation When Used With Standard Nebulizer -
- Results Presented at American Association of Immunologists Meeting -
CHESHIRE, Conn., May 15 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced research findings showing that its anti-C5 monoclonal antibody can be effectively delivered to the lungs to substantially block airway inflammation and hyperresponsiveness in preclinical models of acute severe allergic asthma. The compound used in the research is a surrogate of eculizumab, Alexion's lead anti-complement antibody. The study shows that anti-C5 ...